Minerva Neurosciences | NERV - Net Income


Minerva Neurosciences reported $1.44M in Net Income for its fiscal quarter ending in December of 2024.





Net Income Change Date
Acadia Pharmaceuticals USD 273.57M 201.79M Dec/2025
Adma Biologics USD 49.38M 12.95M Dec/2025
ALKERMES USD 49.34M 33.42M Dec/2025
Alterity Therapeutics Limited AUD -6.3M 525.41K Dec/2025
AstraZeneca USD 2.33B 207M Dec/2025
BioCryst Pharmaceuticals USD 245.84M 232.95M Dec/2025
Bristol-Myers Squibb USD 1.09B 1.11B Dec/2025
Cipla INR 6.76B 6.75B Dec/2025
Clal Biotechnology ILS -6.17M 15.56M Dec/2022
Compugen USD 56.84M 63.82M Dec/2025
CSL USD 401M 96.5M Dec/2025
Eli Lilly USD 6.64B 1.05B Dec/2025
Esperion Therapeutics USD 61.83M 93.16M Dec/2025
GlaxoSmithKline GBP 636M 1.38B Dec/2025
Grifols EUR 114.37M 34.03M Dec/2025
Halozyme Therapeutics USD -141.59M 316.82M Dec/2025
Ionis Pharmaceuticals USD -229M 100.39M Dec/2025
J&J USD 5.12B 36M Dec/2025
Merck USD 2.96B 2.82B Dec/2025
Minerva Neurosciences USD 1.44M 21.07M Dec/2024
Neurocrine Biosciences USD 209.5M 102M Sep/2025
Novartis USD 2.41B 1.52B Dec/2025
Novavax USD 17.53M 219.91M Dec/2025
Pfizer USD -1.65B 5.19B Dec/2025
Roche Holding CHF 5.47B 1.76B Dec/2025
Sanofi EUR -801M 3.6B Dec/2025
Takeda JPY 103.64B 115.44B Dec/2025
Vanda Pharmaceuticals USD -18.9M 13.58M Dec/2024